Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Cancer, Second Primary

imatinib mesylate has been researched along with Cancer, Second Primary in 57 studies

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's28 (49.12)29.6817
2010's28 (49.12)24.3611
2020's1 (1.75)2.80

Authors

AuthorsStudies
Akami, T; Hatakeyama, T; Komiyama, S; Mazaki, T; Ogino, S; Sakai, K; Tamai, H; Ueda, Y1
Comandini, D; Damiani, A; Damiano, G; Grassi, M; Martelli, V; Prelaj, A; Rebuzzi, SE1
Coha, B; Holik, H; Kovač Peić, A; Novaković, S1
An, ZM; Li, F; Mei, JG; Song, P; Tang, YM; Wang, LP; Yu, YP; Zhai, YP; Zhou, XG1
Abruzzese, E; Albano, F; Baccarani, M; Bigazzi, C; Binotto, G; Bonifacio, M; Breccia, M; Caracciolo, C; Castagnetti, F; Cavazzini, F; Cavo, M; D'Adda, M; Foà, R; Gugliotta, G; Intermesoli, T; Iurlo, A; La Barba, G; Levato, L; Martinelli, G; Martino, B; Pane, F; Pregno, P; Rosti, G; Saglio, G; Sorà, F; Soverini, S; Stagno, F; Tiribelli, M1
Bi, L; Duan, J; Fan, Z; Pan, L; Qiao, W; Wu, D; Yang, M1
Koya, J; Kurokawa, M; Morita, K; Nakamura, F; Toya, T1
Kou, Y; Wang, Q; Yang, R1
Dogan, NU; Gungor, T; Karsli, F; Sahin, I1
Onoda, M; Shono, K; Togasaki-Yoshimoto, E; Yokota, A1
Cho, HS; Hyun, MS; Kim, MK; Koh, SA; Lee, HY; Lee, KH1
Fujii, M; Honma, M; Iizuka, H; Ishida-Yamamoto, A; Iwasaki, T; Kishiyama, K; Takahashi, H; Takahashi, I1
Baerlocher, GM; Brümmendorf, TH; Fabarius, A; Fauser, AA; Flasshove, M; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Hess, U; Hochhaus, A; Hofmann, WK; Hossfeld, DK; Kolb, HJ; Kraus, MP; Krause, SW; Lauseker, M; Mahlberg, R; Miranda, MB; Müller, MC; Neben, K; Nerl, C; Pfirrmann, M; Plöger, C; Proetel, U; Prümmer, O; Rendenbach, B; Saußele, S; Verbeek, W1
Inayat, F; Saif, MW1
Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M1
Cortes, J; Fava, C1
Hino, M; Koh, KR; Nakamae, H; Ohsawa, M; Osugi, H; Sakamoto, E; Sawada, T; Wakasa, K; Yamane, T1
Branford, S; Druker, BJ; Foroni, L; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Hughes, TP; Larson, RA; Mone, M; Müller, MC; O'Brien, SG; Radich, JP; Rudoltz, M1
Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC1
Kata, D; Kyrcz-Krzemień, S; Mrówka-Kata, K; Najda, J; Pajak, J; Seweryn, M1
Bittencourt, H; Castro, LC; Clementino, NC; Freitas, IF; Macedo, AV; Mendes, CU; Oliveira, FB; Rego, EM; Resende, C; Vieira, AK1
Imai, T; Machida, T; Shima, Y; Uemura, Y1
Asou, N; Iwanaga, E; Mitsuya, H; Nanri, T1
Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M1
Abreu, MH; Gomez, RS; Resende, RG; Silva, ME; Teixeira, RG; Vasconcelos, Fde O1
Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM1
Agarwal, JP; Banavali, S; Budrukkar, A; Chatturvedi, P; D'Cruz, A; Laskar, SG; Murthy, V; Muttagi, S; Shahid, T1
Besen, A; Disel, U; Duman, BB; Gurkan, E; Paydas, S1
Stein, BL1
Ajioka, Y; Hatakeyama, K; Hirota, S; Ishikawa, T; Kanda, T; Kosugi, S; Mashima, Y; Ohashi, M; Suzuki, S; Yajima, K1
Butrynski, J; Hornick, JL; Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Shinagare, AB; Zukotynski, KA1
Fujiwara, T; Fukuhara, N; Harigae, H; Inokura, K; Ishizawa, K; Katsuoka, Y; Okitsu, Y; Onishi, Y; Shimosegawa, K1
Bianchino, G; D'Arena, G; D'Auria, F; Deaglio, S; Del Vecchio, L; Gemei, M; Grieco, V; Guariglia, R; Luciano, L; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Statuto, T; Villani, O1
Clark, RE; Lin, K; Salim, R; Wang, L1
Chee, YL; Culligan, DJ; Holyoake, TL; Stevenson, D; Vickers, MA1
Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J1
Blaise, D; Caillères, S; Lafage-Pochitaloff, M; Maurice, C; Mozziconacci, MJ; Sainty, D; Vey, N1
Jin Huh, H; Lee, M; Myong Seong, C; Soon Chung, W; Won Huh, J1
Bekkenk, MW; Jansen, PM; Meijer, CJ; Middeldorp, JM; Stevens, SJ; Vermeer, MH; Willemze, R1
Chand, M; Keung, YK; Thakuri, M1
Freeman, A; Neumann, Y; Rechavi, G; Toren, A; Waldman, D; Weintraub, M1
Guilhot, F; Guilhot, J; Larchée, R; Martineau, G; Roy, L1
Larson, RA1
Azzara', A; Carulli, G; Fazzi, R; Galimberti, S; Orciuolo, E; Petrini, M; Testi, C1
Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Piccirillo, N; Reddiconto, G; Sica, S; Sorà, F1
Hatfield, A; Owen, S; Pilot, PR; Sablinska, K1
Baer, MR; Dunford, LM; Lawrence, W; McCarthy, PL; Ramanarayanan, J; Sait, SN1
Frazão Rosa, Fde O; Maria Morselli, F; Ommati, LV; Rodrigues Oliveira, JS; Rosário Cavalheiro, Rde C; Vicari, P1
Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M1
Alimena, G; Biondo, F; Breccia, M; Diverio, D; Frustaci, A; Gentilini, F; Nanni, M; Pane, F; Russo, E1
Higuchi, M; Nishinaka, H; Yamano, Y1
Bidoli, P; Casali, PG; Casieri, P; Miselli, F; Negri, T; Orsenigo, M; Piacenza, C; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E1
Browett, PJ; Jackson, SR; Ross, DM1
Alimena, G; Breccia, M; Cannella, L; Finolezzi, E; Frustaci, A; Levi, A; Martelli, M; Russo, E; Stefanizzi, C1
Gollard, R; Trent, J; Wierda, W1
Alberti, L; Arifi, S; Blay, JY; Cassier, P; Decouvelaere, AV; Dufresne, A; El Sayadi, H; Fayette, J; Méeus, P; Ranchère, D; Ray-Coquard, I; Tabone-Eglinger, S1
Cortes, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Vega-Ruiz, A1

Reviews

8 review(s) available for imatinib mesylate and Cancer, Second Primary

ArticleYear
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
    Annals of hematology, 2018, Volume: 97, Issue:6

    Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome

2018
Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma.
    The Korean journal of internal medicine, 2014, Volume: 29, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Chemoradiotherapy; Cyclophosphamide; Doxorubicin; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vincristine; Whole Body Imaging

2014
Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.
    Leukemia research, 2010, Volume: 34, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Testicular Neoplasms; Young Adult

2010
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine

2011
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
    Human pathology, 2012, Volume: 43, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic

2012
Secondary malignancy after imatinib therapy: eight cases and review of the literature.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:9

    Topics: Adult; Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult

2012
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
    American journal of hematology, 2003, Volume: 74, Issue:3

    Topics: Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction

2003
[Imatinib and solid tumours].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasms; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms

2008

Trials

3 trial(s) available for imatinib mesylate and Cancer, Second Primary

ArticleYear
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
    Haematologica, 2017, Volume: 102, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate

2017
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
    Leukemia, 2016, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Incidence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Sex Factors

2016
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
    Leukemia, 2009, Volume: 23, Issue:6

    Topics: Benzamides; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome

2009

Other Studies

46 other study(ies) available for imatinib mesylate and Cancer, Second Primary

ArticleYear
[A Case of Omental Desmoid Tumor after a Small Bowel Resection for Gastrointestinal Stromal Tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Omentum

2019
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis.
    Neoplasma, 2020, Volume: 67, Issue:6

    Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasms, Second Primary; Prognosis; Retrospective Studies

2020
Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.
    Acta clinica Belgica, 2017, Volume: 72, Issue:6

    Topics: Aged; Antineoplastic Agents; Ascites; Cecal Neoplasms; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Neuroendocrine Tumors

2017
[Acute Promyelocytic Leukemia Developed during Imatinib Therapy for Gastrointestinal Stromal Tumors].
    Zhongguo shi yan xue ye xue za zhi, 2017, Volume: 25, Issue:2

    Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Tretinoin

2017
Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.
    Breast cancer (Tokyo, Japan), 2017, Volume: 24, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mammography; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Sentinel Lymph Node Biopsy; Ultrasonography, Doppler, Color

2017
Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
    Journal of biosciences, 2018, Volume: 43, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Drug Resistance, Neoplasm; Early Diagnosis; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Male; MicroRNAs; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; ROC Curve

2018
Cancer of cervical stump diagnosed in a woman with chronic myelogenous leukaemia.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2013, Volume: 33, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Uterine Cervical Neoplasms

2013
The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Young Adult

2014
Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
    The Journal of dermatology, 2015, Volume: 42, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Skin Neoplasms

2015
New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
    Anticancer research, 2016, Volume: 36, Issue:11

    Topics: Aged; Carcinoma, Squamous Cell; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Mas; Skin Neoplasms

2016
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
    Leukemia research, 2017, Volume: 54

    Topics: Adult; Aged; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome

2017
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
    American journal of hematology, 2008, Volume: 83, Issue:9

    Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 13; Clone Cells; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines; Trisomy

2008
Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.
    International journal of hematology, 2008, Volume: 88, Issue:3

    Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines

2008
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2009
Granulocytic sarcoma of the stomach: relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia.
    Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines; Sarcoma, Myeloid; Stomach Neoplasms; Transplantation, Homologous

2010
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur

2010
Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.
    Haematologica, 2010, Volume: 95, Issue:9

    Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Remission Induction

2010
Imatinib-associated hyperpigmentation of the palate in post-HSCT patient.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:5

    Topics: Adult; Antineoplastic Agents; Benzamides; Ear Diseases; Ear, External; Facial Dermatoses; Hematopoietic Stem Cell Transplantation; Humans; Hyperpigmentation; Imatinib Mesylate; Male; Maxillary Diseases; Neoplasms, Second Primary; Neurofibromatosis 1; Nose Diseases; Palate, Hard; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Tissue Conditioning, Dental

2012
Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.
    The British journal of oral & maxillofacial surgery, 2012, Volume: 50, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Follow-Up Studies; Gingival Neoplasms; Humans; Hydroxyurea; Hypopharyngeal Neoplasms; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Neoplasms; Neoplasms, Second Primary; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tongue Neoplasms

2012
Chronic myeloid leukemia and risk of second malignancy in two eras of treatment.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:9

    Topics: Benzamides; Female; Humans; Imatinib Mesylate; Male; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2012
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome

2012
Esophageal gastrointestinal stromal tumor: report of 7 patients.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2012, Apr-27, Volume: 12

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Electronic Health Records; Esophageal Neoplasms; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome

2012
Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Annals of hematology, 2012, Volume: 91, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Consolidation Chemotherapy; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Leukemia, Promyelocytic, Acute; Male; Medication Adherence; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Translocation, Genetic

2012
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Flow Cytometry; Genome, Human; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Progenitor Cells; Myeloid Progenitor Cells; Neoplasms, Second Primary; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles

2012
Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:11

    Topics: Benzamides; Clone Cells; Disease Progression; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines

2002
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
    Leukemia, 2003, Volume: 17, Issue:3

    Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines

2003
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
    European journal of haematology, 2003, Volume: 70, Issue:4

    Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Coronary Disease; Drug Eruptions; Dyspnea; Enzyme Inhibitors; Facial Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Sunlight; Ultraviolet Rays

2003
Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Leukemia, 2003, Volume: 17, Issue:9

    Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines

2003
EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.
    Blood, 2003, Dec-01, Volume: 102, Issue:12

    Topics: Aged; B-Lymphocytes; Benzamides; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoproliferative Disorders; Neoplasms, Second Primary; Piperazines; Pyrimidines; Skin Neoplasms

2003
Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
    Leukemia, 2004, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines

2004
Favorable early response of secondary chronic myeloid leukemia to imatinib.
    American journal of hematology, 2004, Volume: 75, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines; Treatment Outcome

2004
Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.
    Leukemia, 2005, Volume: 19, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines

2005
Adult ALL: where are we and where are we going?
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:6

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Middle Aged; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis

2004
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
    Leukemia research, 2006, Volume: 30, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Interferons; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Rituximab; Treatment Outcome

2006
Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Adult; Antineoplastic Agents; Benzamides; Brain Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines

2006
Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.
    Leukemia, 2006, Volume: 20, Issue:1

    Topics: Adult; Aged; Benzamides; Cohort Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Time

2006
Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
    Leukemia research, 2006, Volume: 30, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Time Factors; Transplantation, Homologous

2006
Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
    American journal of hematology, 2006, Volume: 81, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Radiography; Sarcoma, Myeloid

2006
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome

2006
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Leukemia research, 2006, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Benzamides; Cytogenetic Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Rectal Neoplasms; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Treatment Outcome

2006
[A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fusion Proteins, bcr-abl; Gastrectomy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur

2006
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
    British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1

    Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chordoma; Disease Progression; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sensitivity and Specificity

2007
Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:6

    Topics: Acute Disease; Antineoplastic Agents; Benzamides; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines

2007
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
    Leukemia research, 2008, Volume: 32, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Rituximab

2008
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-10, Volume: 25, Issue:29

    Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Stomach Neoplasms; Treatment Outcome

2007
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
    Leukemia research, 2008, Volume: 32, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine

2008